Finance entity
Every one of those 1 sits in a single category, earnings. William Mccamey is most often covered alongside Aligos Therapeutics, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 5.2 in the same window.
Last mentioned: Aug 9, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. William Mccamey is most often covered alongside Aligos Therapeutics, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 5.2 in the same window. They are less corroborated than the beat average, carrying 2 original sources each against 2.2 for the same window. We currently track 1 Finance story that mention William Mccamey, all published on August 9, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 30 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering William Mccamey. Shared-story counts are live from our verified record — not editorial picks.
Atlanticus Holdings (ATLC) delivered a $2.50 EPS, beating by $0.08, on solid profitability metrics. Simultaneously, insiders including the CFO sold $7.87 million in shares, raising questions about alignment. With a P/E of 16.69 and beta of 2.11, the stock remains a volatile play in consumer credit.
William Mccamey is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
